A Phase 1 interventional study of NNC0487-0111 and Placebo (NNC0487-0111) in Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.
Among the 24 studies testing zenagamtide in Obesity, this one is the 22nd largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 1, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 2 started in 2023.
This study's enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 360 across the 24 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 24 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 147th largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 85 in phase 1, and was the 110th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing zenagamtide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.
Key inclusion criteria
Key exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once-daily oral administration - 1 of 3 different doses
Drug: NNC0487-0111
Once-daily oral administration - 1 of 3 different doses
Drug: Placebo (NNC0487-0111)
Participants will get one tablet to swallow at the same time of the day.
Participants will get one tablet to swallow at the same time of the day.
Number of treatment emergent adverse events (TEAE)
Number of events
Time frame: From pre-dose on Day 1 until completion of the end of study visit Day 31
AUC,MD; the area under the NNC0487-0111 plasma concentration-time curve after last multile dose
h\*nmol/L
Time frame: From pre-dose on Day 10 until Day 11 (24 hours post-dose)
Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose
nmol/L
Time frame: From pre-dose on Day 10 until completion of the end of study visit Day 31
tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose
hour
Time frame: From pre-dose on Day 10 until completion of the end of study visit Day 31
Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Dec 2023, 3 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zenagamtide